Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus (2016) Gerstner S, Köhler W, Heidkamp GF, Purbojo A, Uchida S, Ekici AB, Heger L, et al. Journal article Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment (2016) Heidkamp GF, Sander J, Lehmann C, Heger L, Eissing N, Baranska A, Lühr J, et al. Journal article Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study (2016) Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, et al. Journal article The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia (2016) Finkel P, Frey B, Mayer F, Bösl K, Werthmöller N, Mackensen A, Gaipl U, Ullrich E Journal article Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome (2016) Voelkl S, Rensing-Ehl A, Allgäuer A, Schreiner E, Lorenz MR, Rohr J, Klemann C, et al. Journal article Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects (2015) Meinhardt K, Kroeger I, Bauer R, Ganss F, Ovsiy I, Rothamer J, Büttner M, et al. Journal article NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation (2015) Jacobs B, Tognarelli S, Poller K, Bader P, Mackensen A, Evelyn U Journal article Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma (2015) Bruns H, Büttner M, Fabri M, Mougiakakos D, Bittenbring JT, Hoffmann M, Beier F, et al. Journal article What opportunities does Immuno-oncology indicate for overarching long-term survival? (2015) Bergmann L, Brugger W, Herr W, Mackensen A, Multhoff G Journal article Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial (2015) Rollig C, Serve H, Huettmann A, Noppeney R, Mueller-Tidow C, Krug U, Baldus CD, et al. Journal article